Researcher in Elasmogen Ltd receives prestigious fellowship worth £2 M to help establish him as a future leader of UK bioscience | 08.09.2021

Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship (FLF) Scheme. Dr Obinna Ubah, heads up Scottish biotechnology company Elasmogen Ltd’s auto-immune and anti-inflammation research efforts, and has received a £2 M research award of which £1.57 M is a grant […]

Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners | 25.01.2021

At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland:  Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR and soloMERTM biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially […]

Elasmogen announces grants of 2 new VNAR and soloMER patent families | 09.12.2020

New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland:  Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a significant development in its comprehensive intellectual property position as two new patent families go to grant in multiple territories.  These […]

Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics | 05.05.2020

Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by each of the partners. The collaboration combines Elasmogen’s soloMER™ technology, small (11 kDa) single-chain  binding domains that can be rapidly re-formatted to generate super-neutralizers (bivalent, […]

Elasmogen nominated for Innovative Collaboration award with Almac Discovery | 24.01.2020

Elasmogen has been nominated for a Life Science Award with Almac Discovery in the Innovative Collaboration category. The finalists in the Innovative Collaboration award, sponsored by @MarksClerkScot are announced! They are @ElasmogenLtd , @iCAIRD_Scot , and @MedtronicUK . Find out who wins at #ScotLiSciAwards on 19 March – tickets available at https://t.co/z5f5tnBLNS pic.twitter.com/9Q7SOYezme — LifeScienceAwardScot […]